Please login to the form below

Not currently logged in
Email:
Password:

Par buys Anchen in $410m deal

US-based Par Pharmaceutical is to purchase generic medicines manufacturer Anchen Pharmaceuticals

Par Pharmaceutical Companies is to acquire Anchen Pharmaceuticals, a privately owned speciality pharmaceutical company focused on developing and commercialising extended release and niche generic products, for $410m (€283.6m) in cash.

California-based Anchen has five commercialised products, 27 abbreviated new drug applications (ANDAs) on file with the US Food and Drugs Administration (FDA), five of which are believed to be first-to-file and has 26 additional products in development. Anchen also anticipates launching up to 10 niche generic products during the next two years.

Patrick G LePore, chairman, chief executive and president of Par, said: "This transaction accelerates the expansion of Par's research and development infrastructure and reinforces our strategy to provide long-term sustainable growth. Anchen has an excellent development track record and robust product pipeline, which, when combined with Par's existing capabilities and pipeline, more than doubles our product opportunities."

The acquisition is subject to conditions and approvals and is expected to be complete by the end of the year.

25th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics